AI in Genomics Market to Hit USD 58.62 Bn by 2035 | CAGR 42.3%

Read more about this report- AI in Genomics Market to Hit USD 58.62 Bn by 2035 | CAGR 42.3%

• The AI in Genomics Market is valued at USD 1.21 billion in 2024.
• The AI in Genomics Market will achieve USD 58.62 billion by 2035 through a projected 42.3% CAGR from 2025 to 2035.
• The four primary drivers in the adoption of AI in genomics include the increase in investments in precision medicine, the expansion of genomics databases, the increased need for detecting diseases at earlier stages, and the growing sophistication of genomic data. The success of deep learning and neural networks in neural networks and natural language processing makes it possible to interpret genomic data in real time, which can be used to support the individual approach to treatment.
• The AI in Genomics market is divided into software, hardware, and services as the segments based on offering. Software solutions delivered by AI are the most popular on the market since they are the most scalable and can handle huge amounts of data, whereas services like consulting and integration are becoming more prevalent to assist in covering the entire process of AI implementation in research and clinical environments.
• The market includes machine learning, deep learning, and natural language processing, all by technologies. Deep learning, in particular, is widely used in the identification of rare genetic variants and risk prediction analysis. In the Functionality clause, AI promotes gene expression analysis, genome sequencing, variant calling, and clinical diagnosis, and through this, scientists and clinicians can run an automated drug discovery and development pathway.
• This market is segmented based on end-users because pharmaceutical and biotech companies, healthcare providers, academic & research institutes, and government organizations represent a major part of the market. The education organization and research centers use AI to discover new associations between genes and diseases, and pharmaceutical companies use AI to discover biomarkers and stratify patients.
• Leading players in the change of this market are referred to as IBM, Microsoft, NVIDIA, and Deep Genomics. These technology leaders and genomics pioneers disrupt the market with the strategy of valuable partnerships, platforms using AI, and high-throughput computing skills.
• Geographically, the AI in Genomics market covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The U.S. controls the global market due to the availability of strong AI infrastructure, the availability of funding for genomics research, and extensive genomic data collection. Asia Pacific, on the other hand, is experiencing drastic development due to the government-driven genomics programs and the growing AI investments in states such as China and India.
• AI adoption in genomics is a paradigm shift in the field of healthcare, which leads to personalized, predictive, and preventive medicine. As the world of data-driven advances keeps on developing, the market will serve as one of the foundations of the health care revolution of the future.